Clinical Trial Update: Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients [Phase 1]

View source ↗

Summary

Phase 1 trial update on crizotinib plus pembrolizumab in ALK-positive advanced non-small cell lung cancer; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Crizotinib (crizotinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Pfizer | Conditions: ALK-positive Advanced NSCLC | Phase 1 | Status: TERMINATED | Results posted: 2019-07-01